Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Emerging markets hedge funds navigate turmoil, uncertainty to produce strong gains

Friday, August 29, 2014
Opalesque Industry Update - Hedge funds investing in Emerging Markets posted strong gains through mid - year , increasing total EM hedge fund assets to an eighth consecutive quarterly record, despite a sovereign debt default by Argentina and continuing geopolitical uncertainty in Ukraine, Syria, Israel, Iran and Iraq. Total hedge fund capital invested in Emerging Markets hedge funds increased to over $184 billion (1.13 trillion RMB, 421 billion Brazilian Real, 6.65 trillion Russian Rouble, 690 billion Riyal, 11.1 trillion Indian Rupee), according to the latest HFR Emerging Markets Hedge Fund Industry Report, released today by HFR, the established global leader in the indexation, research and analysis of the global hedge fund industry.

The asset increase of $9 billion of total EM Assets was entirely performance - based, with EM funds experiencing a minor net asset outflow of less than $200 million, while t he total number of EM hedge funds increased to over 1,150, a new record.

The HFRX Russia Index posted a gain of +13.8 percent in 2Q14, recovering the steep loss of - 12.5 percent from 1Q14 and topping the YTD decline of Russian equities by approximately 1,000 basis points. Similarly, the HFRI Russia/Eastern Europe Index, which includes an even wider base of regional hedge fund strategies, gained +7.0 percent in 2Q, nearly recovering the decline of - 8.0 percent from the volatile 1Q. As a result of the strong performance gains, total global hedge fund capital invested Russian and Eastern Europe increased to more than $26 billion, a new record.

Hedge funds investing in Emerging Asia also produced strong gains, with the HFRX India Index up +18.5 percent for the period, extending the YTD gain of the volatile India Index to +26.7 percent. The HFRI China Index gained +0.9 percent in 2Q and +2.90 percent in July, erasing 1Q losses and extending the YTD gain to +1.0 percent. Total global capital invested in hedge funds focusing on Emerging Asia increased to nearly $50 billion, while the number of funds increased to over 520.

Despite an escalation of regional geopolitical turmoil and military activity, the HFRX MENA Index returned +2.3 percent in 2Q, bringing YTD performance, inclusive of a July gain, to +3.1 percent. Approximately 50 hedge funds managing nearly $4.2 billion in vest with a dedicated focus on the Middle East. Similarly, despite the expectations for, and eventual reality of, sovereign default by Argentina, the HFRX Latin America Index gained +5.8 percent in 2Q14; inclusive of a subsequent decline of - 1.0 in July, the LatAm Index has gained +2.8 percent YTD 2014. Over 100 fund s collectively managing over $11 b illion invest with a dedicated focus on Latin America.

“Emerging Markets hedge funds posted a strong recovery from early year losses in the second quarter, providing additional and further evidence of strong EM hedge fund performance available to investors which have the sophistication, risk and volatility tolerance required to monetize these gains,” stated Kenneth J. Heinz, President of HFR. “Despite recent gains for broad market indices in both e merging and developed markets, multiple geopolitical catalysts for market volatility remain salient to global investors, including fluid situations in Syria, Iran, Iraq, Israel, and Ukraine/Russia. EM hedge funds offer global investors the best opportunity to access the most opportunistic, tactical exposure to volatile, dynamic trends across EM equity, currency and fixed income exposures, and these powerful trends are likely to drive continued record assets to EM hedge funds in 2H14.”
PD

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for